Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
ARWR Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-14
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals a net loss compared to a prior net income, increased operating expenses, and a significant revenue decline due to the absence of last year's transaction. While there is a strong cash position and positive payer feedback, the financial performance is weak, with only modest sales of REDEMPLO. The Q&A indicates cautious optimism but lacks specific guidance, which could concern investors. Considering the market cap of $3.19 billion, these factors suggest a negative stock price movement in the next two weeks.
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Positive2-6
The earnings call reveals strong financial performance, with a significant increase in net income and revenue driven by collaboration agreements. Product development updates, including the commercial launch of REDEMPLO and partnerships with Novartis and Sarepta, are promising. However, management's avoidance of specific questions in the Q&A might cause slight concern. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
ARWR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
